Discovery of sialyl Lewis A and Lewis X modified protein cancer biomarkers using high density antibody arrays

Journal of Proteomics

Volumn 96, Issue , 2014, Pages 291-299

  Rho, Jung hyun ^a   Mead, Judson R ^a   Wright, W Shea ^b   Brenner, Dean E ^c,e   Stave, James W ^d   Gildersleeve, Jeffrey C ^b   Lampe, Paul D ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d SDIX   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antibody array; Cancer biomarker; Glycans; Glycoproteins; Lewis X; Sialyl Lewis A

Indexed keywords

GLYCOPROTEIN; SIALYL LEWIS A ANTIGEN; SIALYL LEWIS X ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ARTICLE; CARBOHYDRATE ANALYSIS; CLINICAL ARTICLE; COLON CANCER; CROSS REACTION; FEMALE; HIGH DENSITY ANTIBODY ARRAY; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOBLOTTING; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN MICROARRAY; PROTEIN MODIFICATION; PROTEIN PURIFICATION;

ANTIBODY ARRAY; CANCER BIOMARKER; GLYCANS; GLYCOPROTEINS; LEWIS X; SIALYL LEWIS A;

ANTIBODIES, NEOPLASM; COLONIC NEOPLASMS; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; NEOPLASM PROTEINS; OLIGOSACCHARIDES; PROTEIN ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84890331323     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.10.030     Document Type: Article

References (30)

1. Apweiler R., Hermjakob H., Sharon N. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim Biophys Acta 1999, 1473:4-8.
2. Varki A., Kannagi R., Toole B.P. Glycosylation changes in cancer. Essentials of glycobiology 2009, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. 2nd ed. A. Varki, R.D. Cummings, J.D. Esko, H.H. Freeze, P. Stanley, C.R. Bertozzi, G.W. Hart, M.E. Etzler (Eds.).
3. Adamczyk B., Tharmalingam T., Rudd P.M. Glycans as cancer biomarkers. Biochim Biophys Acta 2012, 1820:1347-1353.
4. Reis C.A., Osorio H., Silva L., Gomes C., David L. Alterations in glycosylation as biomarkers for cancer detection. J Clin Pathol 2010, 63:322-329.
5. Drake P.M., Cho W., Li B., Prakobphol A., Johansen E., Anderson N.L., et al. Sweetening the pot: adding glycosylation to the biomarker discovery equation. Clin Chem 2009, 56:223-236.
6. Wada Y., Azadi P., Costello C.E., Dell A., Dwek R.A., Geyer H., et al. Comparison of the methods for profiling glycoprotein glycans-HUPO human disease glycomics/proteome initiative multi-institutional study. Glycobiology 2007, 17:411-422.
7. Yue T., Partyka K., Maupin K.A., Hurley M., Andrews P., Kaul K., et al. Identification of blood-protein carriers of the CA 19-9 antigen and characterization of prevalence in pancreatic diseases. Proteomics 2011, 11:3665-3674.
8. Hashii N., Kawasaki N., Itoh S., Nakajima Y., Harazono A., Kawanishi T., et al. Identification of glycoproteins carrying a target glycan-motif by liquid chromatography/multiple-stage mass spectrometry: identification of Lewis x-conjugated glycoproteins in mouse kidney. J Proteome Res 2009, 8:3415-3429.
9. Haab B.B., Yue T. High-throughput studies of protein glycoforms using antibody-lectin sandwich arrays. Methods Mol Biol 2011, 785:223-236.
10. Yue T., Goldstein I.J., Hollingsworth M.A., Kaul K., Brand R.E., Haab B.B. The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays. Mol Cell Proteomics 2009, 8:1697-1707.
11. Wu Y.M., Nowack D.D., Omenn G.S., Haab B.B. Mucin glycosylation is altered by pro-inflammatory signaling in pancreatic-cancer cells. J Proteome Res 2009, 8:1876-1886.
12. Yue T., Maupin K.A., Fallon B., Li L., Partyka K., Anderson M.A., et al. Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers. PLoS One 2011, 6:e29180.
13. Magnani J.L., Nilsson B., Brockhaus M., Zopf D., Steplewski Z., Koprowski H., et al. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem 1982, 257:14365-14369.
14. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990, 85:350-355.
15. Kouri M., Pyrhonen S., Kuusela P. Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma. J Surg Oncol 1992, 49:78-85.
16. Iwata T., Nishiyama N., Nagano K., Izumi N., Tsukioka T., Chung K., et al. Preoperative serum value of sialyl Lewis X predicts pathological nodal extension and survival in patients with surgically treated small cell lung cancer. J Surg Oncol 2012, 105:818-824.
17. Remmers N., Anderson J.M., Linde E.M., Dimaio D.J., Lazenby A.J., Wandall H.H., et al. Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer. Clin Cancer Res 2013, 19:1981-1993.
18. Croce M.V., Salice V.C., Lacunza E., Segal-Eiras A. Alpha 1-acid glycoprotein (AGP): a possible carrier of sialyl lewis X (slewis X) antigen in colorectal carcinoma. Histol Histopathol 2005, 20:91-97.
19. Stocks S.C., Kerr M.A. Neutrophil NCA-160 (CD66) is the major protein carrier of selectin binding carbohydrate groups LewisX and sialyl LewisX. Biochem Biophys Res Commun 1993, 195:478-483.
20. Karlsson N.G., Thomsson K.A. Salivary MUC7 is a major carrier of blood group I type O-linked oligosaccharides serving as the scaffold for sialyl Lewis X. Glycobiology 2009, 19:288-300.
21. Loch C.M., Ramirez A.B., Liu Y., Sather C.L., Delrow J.J., Scholler N., et al. Use of high density antibody arrays to validate and discover cancer serum biomarkers. Mol Oncol 2007, 1:313-320.
22. Rho J.H., Lampe P.D. High-throughput screening for native autoantigen-autoantibody complexes using antibody microarrays. J Proteome Res 2013, 12:2311-2320.
23. Ramirez A.B., Loch C.M., Zhang Y., Liu Y., Wang X., Wayner E.A., et al. Use of a single-chain antibody library for ovarian cancer biomarker discovery. Mol Cell Proteomics 2010, 9:1449-1460.
24. Chen S., Haab B.B. Analysis of glycans on serum proteins using antibody microarrays. Methods Mol Biol 2009, 520:39-58.
25. Online database: specificity of anti-sialyl Lewis A glycolipids (CA19-9) antibody, clone 121SLE. CFG functional glycomics gateway http://www.functionalglycomics.org/glycomics/HServlet?operation=view&sideMenu=no&psId=primscreen_5465.
26. Manimala J.C., Roach T.A., Li Z., Gildersleeve J.C. High-throughput carbohydrate microarray profiling of 27 antibodies demonstrates widespread specificity problems. Glycobiology 2007, 17:17C-23C.
27. Goonetilleke K.S., Siriwardena A.K. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007, 33:266-270.
28. Locker G.Y., Hamilton S., Harris J., Jessup J.M., Kemeny N., Macdonald J.S., et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006, 24:5313-5327.
29. Vestergaard E.M., Hein H.O., Meyer H., Grunnet N., Jorgensen J., Wolf H., et al. Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem 1999, 45:54-61.
30. Brockhausen I. Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep 2006, 7:599-604.